日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial

辅助性阿特珠单抗治疗早期三阴性乳腺癌:ALEXANDRA/IMpassion030随机临床试验

Ignatiadis, Michail; Bailey, Andrew; McArthur, Heather; El-Abed, Sarra; de Azambuja, Evandro; Metzger, Otto; Chui, Stephen Y; Dieterich, Max; Perretti, Thomas; Shearer-Kang, Esther; Molinero, Luciana; Steger, Günther G; Jassem, Jacek; Lee, Soo Chin; Higgins, Michaela; Zarba, Jose; Schmidt, Marcus; Gomez, Henry; Guerrero Zotano, Angel; Moscetti, Luca; Chiu, Joanne; Munzone, Elisabetta; Ben-Baruch, Noa Efrat; Bajetta, Emilio; Ohno, Shinji; Im, Seock-Ah; Werutsky, Gustavo; Gal-Yam, Einav Nili; Gonzalez Farre, Xavier; Tseng, Ling-Ming; Jacot, William; Gluz, Oleg; Shao, Zhimin; Shparyk, Yaroslav; Zimina, Anastasia; Winer, Eric; Cameron, David A; Viale, Giuseppe; Saji, Shigehira; Gelber, Richard; Piccart, Martine

Unique characteristics of autoantibodies targeting MET in patients with breast and lung cancer.

乳腺癌和肺癌患者中针对MET的自身抗体的独特特征

Navon Michal, Ben-Shalom Noam, Dadiani Maya, Mor Michael, Yefet Ron, Bakalenik-Gavry Michal, Chat Dana, Balint-Lahat Nora, Barshack Iris, Tsarfaty Ilan, Nili Gal-Yam Einav, Freund Natalia T

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

奥拉帕尼联合度伐利尤单抗(加或不加贝伐单抗)治疗既往未接受过PARP抑制剂治疗的铂敏感复发性卵巢癌:一项II期多队列研究

Drew, Yvette; Kim, Jae-Weon; Penson, Richard T; O'Malley, David M; Parkinson, Christine; Roxburgh, Patricia; Plummer, Ruth; Im, Seock-Ah; Imbimbo, Martina; Ferguson, Michelle; Rosengarten, Ora; Steeghs, Neeltje; Kim, Min Hwan; Gal-Yam, Einav; Tsoref, Daliah; Kim, Jae-Hoon; You, Benoit; De Jonge, Maja; Lalisang, Roy; Gort, Eelke; Bastian, Sara; Meyer, Kassondra; Feeney, Laura; Baker, Nigel; Ah-See, Mei-Lin; Domchek, Susan M; Banerjee, Susana

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

奈拉替尼+氟维司群+曲妥珠单抗治疗HR阳性、HER2阴性、HER2突变型转移性乳腺癌:SUMMIT试验的结果和生物标志物分析

Jhaveri, K; Eli, L D; Wildiers, H; Hurvitz, S A; Guerrero-Zotano, A; Unni, N; Brufsky, A; Park, H; Waisman, J; Yang, E S; Spanggaard, I; Reid, S; Burkard, M E; Vinayak, S; Prat, A; Arnedos, M; Bidard, F-C; Loi, S; Crown, J; Bhave, M; Piha-Paul, S A; Suga, J M; Chia, S; Saura, C; Garcia-Saenz, J Á; Gambardella, V; de Miguel, M J; Gal-Yam, E N; Rapael, A; Stemmer, S M; Ma, C; Hanker, A B; Ye, D; Goldman, J W; Bose, R; Peterson, L; Bell, J S K; Frazier, A; DiPrimeo, D; Wong, A; Arteaga, C L; Solit, D B

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Margetuximab 与 Trastuzumab 治疗既往接受过治疗的 HER2 阳性晚期乳腺癌患者(SOPHIA):一项随机 3 期试验的最终总生存期结果

Rugo, Hope S; Im, Seock-Ah; Cardoso, Fatima; Cortes, Javier; Curigliano, Giuseppe; Musolino, Antonino; Pegram, Mark D; Bachelot, Thomas; Wright, Gail S; Saura, Cristina; Escrivá-de-Romaní, Santiago; De Laurentiis, Michelino; Schwartz, Gary N; Pluard, Timothy J; Ricci, Francesco; Gwin, William R 3rd; Levy, Christelle; Brown-Glaberman, Ursa; Ferrero, Jean-Marc; de Boer, Maaike; Kim, Sung-Bae; Petráková, Katarína; Yardley, Denise A; Freedman, Orit; Jakobsen, Erik H; Gal-Yam, Einav Nili; Yerushalmi, Rinat; Fasching, Peter A; Kaufman, Peter A; Ashley, Emily J; Perez-Olle, Raul; Hong, Shengyan; Rosales, Minori Koshiji; Gradishar, William J

Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study

雌激素受体阳性早期乳腺癌患者复发评分26-30的临床结局:一项观察性真实世界队列研究

Rotem, Ofer; Peretz, Idit; Leviov, Michelle; Kuchuk, Iryna; Itay, Amit; Tokar, Margarita; Paluch-Shimon, Shani; Maimon, Ofra; Yerushalmi, Rinat; Drumea, Karen; Evron, Ella; Sonnenblick, Amir; Gal-Yam, Einav; Goldvaser, Hadar; Samih, Yosef; Merose, Rotem; Bareket-Samish, Avital; Soussan-Gutman, Lior; Stemmer, Salomon M

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry

第二原发性乳腺癌:复发评分结果、临床病理特征、辅助治疗和预后——Clalit登记研究的探索性分析

Shachar, Shlomit S; Leviov, Michelle; Yerushalmi, Rinat; Drumea, Karen; Tokar, Margarita; Soussan-Gutman, Lior; Bareket-Samish, Avital; Sonnenblick, Amir; Ben-Baruch, Noa; Evron, Ella; Gal-Yam, Einav Nili; Paluch-Shimon, Shani; Bar-Sela, Gil; Goldvaser, Hadar; Stemmer, Salomon M

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

在既往未接受过内分泌治疗的激素受体阳性、HER2阴性晚期乳腺癌患者中,瑞博西尼联合来曲唑治疗:来自3b期CompLEEment-1试验的亚组安全性分析

Borstnar, Simona; Palacova, Marketa; Łacko, Aleksandra; Timcheva, Constanta; Gal-Yam, Einav Nili; Papazisis, Konstantinos; Beniak, Juraj; Kudela, Pavol; Rubovszky, Gábor

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

AURORA(乳腺癌国际协作组 (BIG) 分子筛查计划)中乳腺癌原发灶及其匹配转移灶的基因组和转录组分析

Aftimos, Philippe; Oliveira, Mafalda; Irrthum, Alexandre; Fumagalli, Debora; Sotiriou, Christos; Gal-Yam, Einav Nili; Robson, Mark E; Ndozeng, Justin; Di Leo, Angelo; Ciruelos, Eva M; de Azambuja, Evandro; Viale, Giuseppe; Scheepers, Elsemieke D; Curigliano, Giuseppe; Bliss, Judith M; Reis-Filho, Jorge S; Colleoni, Marco; Balic, Marija; Cardoso, Fatima; Albanell, Joan; Duhem, Caroline; Marreaud, Sandrine; Romagnoli, Dario; Rojas, Beatriz; Gombos, Andrea; Wildiers, Hans; Guerrero-Zotano, Angel; Hall, Peter; Bonetti, Andrea; Larsson, Karolina Fs; Degiorgis, Martina; Khodaverdi, Silvia; Greil, Richard; Sverrisdóttir, Ásgerdur; Paoli, Marta; Seyll, Ethel; Loibl, Sibylle; Linderholm, Barbro; Zoppoli, Gabriele; Davidson, Nancy E; Johannsson, Oskar Th; Bedard, Philippe L; Loi, Sherene; Knox, Susan; Cameron, David A; Harbeck, Nadia; Montoya, Maite Lasa; Brandão, Mariana; Vingiani, Andrea; Caballero, Carmela; Hilbers, Florentine S; Yates, Lucy R; Benelli, Matteo; Venet, David; Piccart, Martine J

Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors

化疗使三阴性乳腺癌中CD8+ TNFR2+ TILs的比例增加

Tamir Baram ,Nofar Erlichman ,Maya Dadiani ,Nora Balint-Lahat ,Anya Pavlovski ,Tsipi Meshel ,Dana Morzaev-Sulzbach ,Einav Nili Gal-Yam ,Iris Barshack ,Adit Ben-Baruch